Psyence Biomedical Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	6.14	0.73	1.33	1.76
Cash & Short-Term Investments	6.14	0.73	1.33	1.76
Cash Growth	736.78%	-45.05%	-23.97%	-
Other Receivables	0.14	0.04	0.15	0.04
Receivables	0.14	0.04	0.15	0.04
Prepaid Expenses	0.25	0.32	0.08	0.01
Restricted Cash	0.04	0.03	0.03	0.03
Total Current Assets	6.56	1.13	1.59	1.83
Property, Plant & Equipment	0.01	0.01	-	-
Long-Term Investments	0.75	-	-	-
Total Assets	7.32	1.13	1.59	1.83
Accounts Payable	0.26	0.56	1.63	0.04
Accrued Expenses	0.05	0.13	0.16	0.09
Short-Term Debt	-	10.45	-	-
Other Current Liabilities	0.28	0.97	-	-
Total Current Liabilities	0.59	12.1	1.79	0.13
Total Liabilities	0.59	12.1	1.79	0.13
Common Stock	61.75	46.13	5.93	1.7
Retained Earnings	-56.45	-57.46	-6.3	-
Comprehensive Income & Other	1.42	0.36	0.17	-
Shareholders' Equity	6.72	-10.97	-0.2	1.7
Total Liabilities & Equity	7.32	1.13	1.59	1.83
Total Debt	-	10.45	-	-
Net Cash (Debt)	6.14	-9.71	1.33	1.76
Net Cash Growth	-	-	-23.97%	-
Net Cash Per Share	253.30	-891.01	-	-
Filing Date Shares Outstanding	0.07	0.02	-	-
Total Common Shares Outstanding	0.07	0.02	-	-
Working Capital	5.97	-10.98	-0.2	1.7
Book Value Per Share	94.32	-489.80	-	-
Tangible Book Value	6.72	-10.97	-0.2	1.7
Tangible Book Value Per Share	94.32	-489.80	-	-
Machinery	0.02	0.01	-	-

Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q